mash wegovy - Search News

Order byBest matchMost fresh

Novo Nordisk, Wegovy and FDA

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

BioPharma Dive · 1d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Contract Pharma · 20h

FDA Approves Novo Nordisk’s Wegovy for MASH

· 1d

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

· 2d

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

· 1d

Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH

· 20h

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

The approval is based on results from the first phase of the ESSENCE trial, which revealed Wegovy’s superior efficacy over placebo in improving liver fibrosis.

· 1d

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

· 1d

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

Medscape1d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.

Pharmaceutical Technology on MSN1d

Wegovy becomes first GLP-1RA to gain FDA MASH approval

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

BioSpace1d

Novo Wins MASH Approval for Wegovy

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.

Endocrinology Advisor1d

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.